Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Prognostic factors for treatment response in patients with lupus nephritis.

Miranda-Hernández D, Cruz-Reyes C, Angeles U, Jara LJ, Saavedra MA.

Reumatol Clin. 2014 May-Jun;10(3):164-9. doi: 10.1016/j.reuma.2013.08.001. Epub 2013 Nov 21. English, Spanish.

2.

The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.

Shen K, Yu Y, Tang Z, Liu Z, Li L.

Chin Med J (Engl). 1997 Jul;110(7):502-7.

PMID:
9594205
3.

Predictive risk factors for failure to induction therapy of lupus nephritis in a cohort of Colombian patients.

Pinto Peñaranda LF, Castro Mercado IL, Duque Caballero V, Márquez Hernández JD, Velásquez Franco CJ.

Reumatol Clin. 2014 May-Jun;10(3):147-51. doi: 10.1016/j.reuma.2013.09.005. Epub 2013 Nov 21. English, Spanish.

4.

Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.

Conlon PJ, Fischer CA, Levesque MC, Smith SR, St Clair EW, Allen NB, Fleming JA, Howell DN.

Clin Nephrol. 1996 Sep;46(3):170-5.

PMID:
8879851
5.

Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis.

Bastian HM, Roseman JM, McGwin G Jr, Alarcón GS, Friedman AW, Fessler BJ, Baethge BA, Reveille JD; LUMINA Study Group. LUpus in MInority populations: NAture vs nurture.

Lupus. 2002;11(3):152-60.

PMID:
12004788
6.

Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.

Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, D'Cruz DP.

Lupus. 2013 May;22(6):574-82. doi: 10.1177/0961203313483376. Epub 2013 Apr 30.

PMID:
23632989
7.

Sustained remission of lupus nephritis.

Barber CE, Geldenhuys L, Hanly JG.

Lupus. 2006;15(2):94-101.

PMID:
16539280
8.

Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia.

Al Arfaj AS, Khalil N, Al Saleh S.

Rheumatol Int. 2009 Jul;29(9):1057-67. doi: 10.1007/s00296-009-0905-8. Epub 2009 Apr 21.

PMID:
19381639
9.

Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure.

Faurschou M, Starklint H, Halberg P, Jacobsen S.

J Rheumatol. 2006 Aug;33(8):1563-9.

PMID:
16881113
10.

Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.

Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D.

Arthritis Care Res (Hoboken). 2011 Mar;63(3):351-7. doi: 10.1002/acr.20397. Epub 2010 Nov 15.

11.

Predictors of renal relapse in Korean patients with lupus nephritis who achieved remission six months following induction therapy.

Moon SJ, Park HS, Kwok SK, Ju J, Choi BS, Park KS, Min JK, Kim HY, Park SH.

Lupus. 2013 Apr;22(5):527-37. doi: 10.1177/0961203313476357. Epub 2013 Feb 19.

PMID:
23423249
12.

Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study.

Erre GL, Bosincu L, Faedda R, Fenu P, Masala A, Sanna M, Taras L, Longu MG, Piras M, Soro G, Satta AE, Passiu G.

Rheumatol Int. 2014 Apr;34(4):535-41.

PMID:
24232504
13.

Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide.

Ciruelo E, de la Cruz J, López I, Gómez-Reino JJ.

Arthritis Rheum. 1996 Dec;39(12):2028-34.

PMID:
8961908
14.

Prognosis of proliferative lupus nephritis subsets in the Louvain Lupus Nephritis inception Cohort.

Vandepapelière J, Aydin S, Cosyns JP, Depresseux G, Jadoul M, Houssiau FA.

Lupus. 2014 Feb;23(2):159-65. doi: 10.1177/0961203313514623. Epub 2013 Dec 3.

PMID:
24300780
15.

Early predictors of outcomes in pediatric lupus nephritis: focus on proliferative lesions.

Wu JY, Yeh KW, Huang JL.

Semin Arthritis Rheum. 2014 Feb;43(4):513-20. doi: 10.1016/j.semarthrit.2013.07.005. Epub 2013 Aug 22.

PMID:
23972330
17.

The outcome of patients with renal involvement in pediatric-onset systemic lupus erythematosus--a 20-year experience in Asia.

Lee PY, Yeh KW, Yao TC, Lee WI, Lin YJ, Huang JL.

Lupus. 2013 Dec;22(14):1534-40. doi: 10.1177/0961203313502110. Epub 2013 Aug 21.

PMID:
23966304
18.

[Clinical course and prognostic factors in lupus nephropathy].

Gamba G, Quintanilla L, del Bosque MD, Chew-Wong A, Correa-Rotter R.

Rev Invest Clin. 2000 Jul-Aug;52(4):397-405. Spanish.

PMID:
11061101
19.

Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis.

Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I, Khamashta MA, D'Cruz D, Hughes GR.

Ann Rheum Dis. 2003 Jun;62(6):556-60.

20.

A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis.

Shaharir SS, Ghafor AH, Said MS, Kong NC.

Lupus. 2014 Apr;23(4):436-42. doi: 10.1177/0961203313518624. Epub 2014 Jan 7.

PMID:
24399814
Items per page

Supplemental Content

Write to the Help Desk